About this Event
MizzouForward Keynote – Bridging the Dosimetry Scales in Radiopharmaceutical Therapy
February 14th | 2:00pm – 3:00pm
Ketcham Auditorium – W1005 Lafferre Hall
Join us for “Bridging the Dosimetry Scales in Radiopharmaceutical Therapy" a keynote presentation by Dr. Bryan Bednarz, College of Engineering – BBCE, MizzouForward faculty candidate. Dr. Bednarz will present on his research for approximately 40-minutes with a 20-minute question and answer session to follow.
Dr. Bryan Bednarz is an Associate Professor with tenure in the Department of Medical Physics at the University of Wisconsin. He completed his BSE and MSE in Nuclear Engineering and Radiologic Sciences (with distinction) from the University of Michigan, Ann Arbor, MI. He earned his PhD in Nuclear Engineering and Science (with distinction) from Rensselaer Polytechnic Institute, Troy, NY.
Radiopharmaceutical Therapy (RPT) has been used for nearly a century (e.g., Na131I) to treat cancer and other diseases, but the incorporation of new radiopharmaceuticals into the armamentarium of oncologists during most of this time has only led to moderate clinical benefit. In recent years, however, the medical community has seen a renaissance of RPT applications stemming from the success of labeling and delivering highly selective drugs with both imaging and therapeutic isotopes into patients, a process that has been coined ‘radiotheranostics’. With a rapidly growing number of radiopharmaceuticals that have been approved for clinical use or are in late-stage clinical trials there is a great opportunity for medical physicist to have a major impact on this burgeoning field in terms of both research and clinical service especially in the context of patient-specific dosimetry. Over the last decade, Professor Bednarz’s lab, the Radiological Engineering and Design (RED) Laboratory, at the University of Wisconsin has been developing novel approaches to perform dosimetry calculations for RPT both in the research and clinical setting. This talk will overview previous dosimetry efforts of the RED Lab for pre-clinical and clinical trials and how these efforts are being translated clinically for a variety of different radiopharmaceuticals. Furthermore, this talk will discuss future growth areas in the field with a particular emphasis on micro- and nanodosimetry.
You can access Dr. Bednarz’s CV via OneDrive here:
CV_Bednarz_2022_Mizzou.pdf (University log in required to access)
After the keynote, please provide candidate feedback with our brief survey.